Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V Arzneimittelbezeichnung: ATC-Code B02BD02; B02BD04
TED · 515009-2026Voluntary ex-ante transparency noticeawardedNo deadline given
Who already wins at this buyer
Firms with recorded awards from AOK Bayern - Die Gesundheitskasse in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| Bayer Vital GmbH | 2 | — | 2026-07-24 |
| Daiichi Sankyo Deutschland GmbH | 1 | — | 2026-06-22 |
| Incyte Biosciences Distribution B.V. | 1 | — | 2026-06-22 |
| Intersero GmbH | 1 | — | 2026-07-24 |
| Novo Nordisk Pharma GmbH | 1 | — | 2026-07-24 |
Full buyer profile: what AOK Bayern - Die Gesundheitskasse buys and who wins it →
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Arzneimittelrabattvertrag § 130a Abs. 8 SGB V Arzneimittelbezeichnung: HAEMOCTIN SDH (R), Blutgerinnungsfaktor VIII ATC-Code B02BD02; HAEMONINE(R), Blutgerinnungsfaktor IX ATC-Code B02BD04